

SUPPLEMENTARY MATERIAL

Supplementary Table 2. Published studies and meta-analysis on *APC* I1307K in AJ or Israeli (ethnicity not reported) breast cancer patients and controls.

Study	Ashkenazi Jewish individuals or Israelis (ethnicity not determined)		
	Breast ca. I1307K / total (%)	Controls I1307K / total (%)	OR (95%CI), P-value ^a
Woodage et al. 1998 [1] (AJ)	25/279 (9.0%)	337/4,724 (7.1%)	1.28 (0.82-1.97), p = 0.2
Redston et al. 1998 [2] (AJ)	59/665 (8.9%)	-	-
Forkosh et al. 2022 [3] (AJ)	295/4,377 (6.7%)	342/4,918 (7.0%)	0.97 (0.82-1.14), p = 0.7
Gershoni-Baruch et al. 2000 [4] (Israeli)	17/382 (4.4%)	23/418 (5.5%)	0.80 (0.39-1.59), p = 0.52
Lieberman et al. 2007 [5] (Israeli)	7/85 (8.2%)	266/3,283 (8.1%)	1.02 (0.39-2.23), p = 0.8
Leshno et al. 2016 [6] (Israeli)	20/153 (13.0%)	614/13,013 (4.7%)	3.04 (0.78-4.92), p = 4.5 x 10 ⁻⁵
TOTAL	423/5,941 (7.1%)	1,582/26,356 (6.0%)	1.20 (1.07-1.34), p = 0.001
TOTAL (AJ only)	379/5321 (7.1%)	679/9642 (7.0%)	1.01 (0.89-1.15), p = 0.9

a. Fisher's exact test. Calculations made for this publication. Results may not coincide with the original publications due to the application of different adjustments to the tests in their analyses.

Supplementary Table 3. Published studies and meta-analysis on *APC* I1307K in AJ or Israeli (ethnicity not reported) prostate cancer patients and controls.

Study	Ashkenazi Jewish individuals or Israelis (ethnicity not determined)		
	Prostate ca. I1307K / total (%)	Controls I1307K / total (%)	OR (95%CI), P-value ^a
Lehrer et al. 2000 [7] (AJ)	10/135 (7.4%)	-	-
Lehrer et al. 2003 [8] (AJ)	11/77 (14.3%)	-	-
Poynter et al. 2006 [9] (AJ)	9/105 (8.6%)	-	-
Forkosh et al. 2022 [3] (AJ)	32/475 (6.7%)	342/4,918 (7.0%)	0.97 (0.64-1.41), p = 0.9
Lieberman et al. 2007 [5] (Israeli)	2/44 (4.5%)	266/3,283 (8.1%)	0.54 (0.06-2.10), p = 0.6
TOTAL	64/836 (7.6%)	608/8,201 (7.4%)	1.03 (0.78-1.36), p = 0.8
TOTAL (AJ only)	62/792 (7.8%)	342/4,918 (7.0%)	1.14 (0.84-1.51), p = 0.4

a. Fisher's exact test. Calculations made for this publication. Results may not coincide with the original publications due to the application of different adjustments to the tests in their analyses.

Supplementary Table 4. Published studies and meta-analysis on *APC* I1307K in AJ or Israeli (ethnicity not reported) pancreatic cancer patients and controls.

Study	Ashkenazi Jewish individuals or Israelis (ethnicity not determined)		
	Pancreatic ca. I1307K / total (%)	Controls I1307K / total (%)	OR (95%CI), P-value ^a
Gryfe et al. 1999 [10] (AJ)	3/35 (8.6%)	-	-
Forkosh et al. 2022 [3] (AJ)	44/473 (9.3%)	342/4,918 (6.9%)	1.37 (0.96-1.91), p = 0.06
Lieberman et al. 2007 [5] (Israeli)	7/58 (13.5%)	266/3,283 (8.1%)	1.56 (0.59-3.49), p = 0.3
Shamai et al. 2015 [11] (Israeli)	11/73 (15.0%)	-	-
Leshno et al. 2016 [6] (Israeli)	13/103 (12.6%)	614/13,013 (4.7%)	2.92 (1.49-5.28), p = 0.001
TOTAL	78/776 (10.0%)	1,222/21,214 (5.7%)	1.82 (1.42-2.33), p = 4.1 x 10⁻⁶
TOTAL (AJ only)	47/508 (9.2%)	342/4,918 (7.0%)	1.36 (0.97-1.89), p = 0.06

a. Fisher's exact test. Calculations made for this publication. Results may not coincide with the original publications due to the application of different adjustments to the tests in their analyses.

REFERENCES

1. Woodage T, King SM, Wacholder S, et al. The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. *Nat Genet* 1998;**20**(1):62-5 doi: 10.1038/1722[published Online First: Epub Date]].
2. Redston M, Nathanson KL, Yuan ZQ, et al. The APC I1307K allele and breast cancer risk. *Nat Genet* 1998;**20**(1):13-4 doi: 10.1038/1666].
3. Forkosh E, Bergel M, Hatchell KE, et al. Ashkenazi Jewish and Other White APC I1307K Carriers Are at Higher Risk for Multiple Cancers. *Cancers (Basel)* 2022;**14**(23) doi: 10.3390/cancers14235875].
4. Gershoni-Baruch R, Patael Y, Dagan, et al. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. *Br J Cancer* 2000;**83**(2):153-5 doi: 10.1054/bjoc.2000.1248].
5. Liberman E, Kraus S, Sagiv E, et al. The APC E1317Q and I1307K polymorphisms in non-colorectal cancers. *Biomed Pharmacother* 2007;**61**(9):566-9 doi: 10.1016/j.biopha.2007.08.016].
6. Leshno A, Shapira S, Liberman E, et al. The APC I1307K allele conveys a significant increased risk for cancer. *Int J Cancer* 2016;**138**(6):1361-7 doi: 10.1002/ijc.29876].
7. Lehrer S, McCurdy LD, Stock RG, et al. Body mass, age, and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients. *Cancer Genet Cytogenet* 2000;**122**(2):131-3 doi: 10.1016/s0165-4608(00)00291-0].
8. Lehrer S, Diamond EJ, Stone NN, et al. Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. *Urol Oncol* 2003;**21**(2):101-4 doi: 10.1016/s1078-1439(02)00210-7].
9. Poynter JN, Cooney KA, Bonner JD, et al. APC I1307K and the risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2006;**15**(3):468-73 doi: 10.1158/1055-9965.EPI-05-0584].
10. Gryfe R, Di Nicola N, Lal G, et al. Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. *Am J Hum Genet* 1999;**64**(2):378-84 doi: 10.1086/302262].
11. Shamaï S, Nabiochtchikov I, Kraus S, et al. CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome. *PLoS One* 2015;**10**(9):e0134469 doi: 10.1371/journal.pone.0134469].